137 related articles for article (PubMed ID: 28240010)
1. PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients.
Elwy F; Helwa R; El Leithy AA; Shehab El din Z; Assem MM; Hassan NH
Asian Pac J Cancer Prev; 2017 Jan; 18(1):57-64. PubMed ID: 28240010
[TBL] [Abstract][Full Text] [Related]
2. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
6. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
7. [PIK3CA gene mutations in Chinese women with HR
Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
[No Abstract] [Full Text] [Related]
8. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations in breast cancer: A Tunisian series.
Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
[TBL] [Abstract][Full Text] [Related]
11. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological Features of
Saikia KK; Panigrahi MK; Mehta A; Kumar D
Indian J Surg Oncol; 2018 Sep; 9(3):381-386. PubMed ID: 30288002
[No Abstract] [Full Text] [Related]
13. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
14. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
15. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
17. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
18. Helical and kinase domain mutations of
Vatte C; Al Amri AM; Cyrus C; Chathoth S; Alsayyah A; Ahmad A; Akhtar MS; Alrashidi NF; Jayaseeli N; Al Wadani H; Al Zahrani A; Al Ali AK
Oncol Lett; 2019 Sep; 18(3):2427-2433. PubMed ID: 31404155
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of
Chao TC; Tsai YF; Liu CY; Lien PJ; Lin YS; Feng CJ; Chen YJ; Lai JI; Hsu CY; Lynn JJ; Huang CC; Tseng LM
Front Oncol; 2023; 13():1192946. PubMed ID: 37655108
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]